Leslie R. Schover on Vaginal Dryness and Pain in Breast Cancer Patients Treated With AIs
Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses vaginal dryness and pain in patients with breast cancer treated with aromatase inhibitors.
Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses vaginal dryness and pain in patients with breast cancer treated with aromatase inhibitors.
It is known that women often experience vaginal dryness and pain after starting aromatase inhibitors. In a survey of women who are sexually active in their first two years of treatment with aromatase inhibitors, nearly 80% reported that they experienced new sexual problems and 25% of women stopped having sex.
Schover says that oncologists have been slow to recognize the destructive nature of aromatase inhibitors. Patients should be encouraged to stay sexually active and consider the use of an over-the-counter vaginal moisturizer, lubricant, and dilator. Schover says her initial impressions are that women are not experiencing as much pain with intercourse compared with those who had no preventive treatment.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
December 7th 2023The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.
